PAT SC1

Drug Profile

PAT SC1

Alternative Names: PAT-SC1; SC-1

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoMab GmbH
  • Developer Patrys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD55 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Gastric cancer

Most Recent Events

  • 13 Sep 2016 Preclinical trials in Gastric cancer in China (IV)
  • 22 Sep 2015 PAT SC1 completes phase-I/II development for Gastric cancer in Germany
  • 25 Jun 2015 PAT SC1 licensed to Hefei Co-source Biomedical in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top